Aurinia Pharmaceuticals Inc (AUPH)
$9.37 -$0.40 (-4.18%) 4:38 PM 12/13/24
NASDAQ | $USD | BiotechnologyStock Data
-
Market Cap
$1.28B -
Day's Range
$9.22 - $9.68 -
Volume
1,598,408 -
52 Week Low / High
$4.71 - $9.74 -
PE Ratio
- -
PEG Ratio
- -
Dividend Frequency
-
- Capital Growth
- Dividend Return to Date
- Dividend Payout year Est.
- Expenses
- Total Return
- Total Return %
- 3
- Strong Buy
- 3
- Buy
- 1
- Hold
- 0
- Sell
- 0
- Strong Sell
- $14.00
- Target Price
Company News
-
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Could Be Less Than A Year Away From Profitability — Sep 27th, 2024
With the business potentially at an important milestone, we thought we'd take a closer look at Aurinia Pharmaceuticals Inc.'s (NASDAQ:AUPH) future prospects. Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to t...
-
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Could Be Less Than A Year Away From Profitability — Sep 27th, 2024
With the business potentially at an important milestone, we thought we'd take a closer look at Aurinia Pharmaceuticals Inc.'s (NASDAQ:AUPH) future prospects. Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to t...
-
ROCKVILLE, Md. & EDMONTON, Alberta, October 11, 2024--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company), announced today the acceptance of six abstracts, including five poster presentations, at the American Society of Nephrology (ASN) Kidney Week 2024 ta...
-
ROCKVILLE, Md. & EDMONTON, Alberta, October 11, 2024--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company), announced today the acceptance of six abstracts, including five poster presentations, at the American Society of Nephrology (ASN) Kidney Week 2024 ta...
-
ROCKVILLE, Md. & EDMONTON, Alberta, October 11, 2024--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company), announced today the acceptance of six abstracts, including five poster presentations, at the American Society of Nephrology (ASN) Kidney Week 2024 ta...
-
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Could Be Less Than A Year Away From Profitability — Sep 27th, 2024
With the business potentially at an important milestone, we thought we'd take a closer look at Aurinia Pharmaceuticals Inc.'s (NASDAQ:AUPH) future prospects. Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to t...
-
ROCKVILLE, Md. & EDMONTON, Alberta, October 11, 2024--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company), announced today the acceptance of six abstracts, including five poster presentations, at the American Society of Nephrology (ASN) Kidney Week 2024 ta...
-
ROCKVILLE, Md. & EDMONTON, Alberta, October 11, 2024--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company), announced today the acceptance of six abstracts, including five poster presentations, at the American Society of Nephrology (ASN) Kidney Week 2024 ta...
-
ROCKVILLE, Md. & EDMONTON, Alberta, October 11, 2024--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company), announced today the acceptance of six abstracts, including five poster presentations, at the American Society of Nephrology (ASN) Kidney Week 2024 ta...
-
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Could Be Less Than A Year Away From Profitability — Sep 27th, 2024
With the business potentially at an important milestone, we thought we'd take a closer look at Aurinia Pharmaceuticals Inc.'s (NASDAQ:AUPH) future prospects. Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to t...
-
ROCKVILLE, Md. & EDMONTON, Alberta, October 11, 2024--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company), announced today the acceptance of six abstracts, including five poster presentations, at the American Society of Nephrology (ASN) Kidney Week 2024 ta...
-
ROCKVILLE, Md. & EDMONTON, Alberta, October 11, 2024--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company), announced today the acceptance of six abstracts, including five poster presentations, at the American Society of Nephrology (ASN) Kidney Week 2024 ta...
-
Aurinia Announces Japan Approval of LUPKYNIS® (Voclosporin) to Treat Lupus Nephritis — Sep 24th, 2024
ROCKVILLE, Md. & EDMONTON, Alberta, September 24, 2024--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that the Japanese Ministry of Health, Labour, and Welfare has approved voclosporin, a second-generation calcineurin inhibitor, in co...
Portfolio
Comprised of 1 portfolios